World’s first Intranasal vaccine iNCOVACC gets Approved by DCGI

World’s first Intranasal vaccine iNCOVACC gets Approved by DCGI

• Bharat Biotech International Limited (BBIL) announced that iNCOVACC (BBV154), has received approval from the Drugs Controller General of India (DCGI) under Restricted Use in Emergency Situations for ages 18 and above, in India, for heterologous booster doses.
• iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule and the heterologous booster dose. iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II, and III clinical trials with successful results.

October Weekly Current Affairs (Persons) Bitbank: Who will replace UU Lalit as 50th Chief Justice of India (CJI)?

                         >> Download Current Affairs PDFs Here

                              Download Sakshi Education Mobile APP

Published date : 30 Nov 2022 05:54PM